This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction
- Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.
- The results which were published in February 2021, indicated that MDMA has the potential to be more effective at treating AUD.
- This data will assist Awakn's progress by enabling a better design and more efficient execution of its clinical program.
- Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.